Key Highlights

  • Curaleaf is running a hostile bid for Aurora Cannabis (NASDAQ:ACB) at a premium of 86%, according to deals coverage on October 26 to 27, 2026, though the reference price behind the premium was not stated.
  • Aurora's board is urging shareholders to reject the offer, which makes the approach hostile: it goes to shareholders directly instead of being agreed with the target's directors.
  • An Alberta regulator dismissed Curaleaf's application to halt Aurora's share program, so Aurora can keep that program running while the contested bid is pending. A regulator ruling is not a verdict on the bid.
  • The 86% premium comes from one deals roundup, and no offer price, payment mix or deadline was captured, so every term should be confirmed against the offer documents.

The Offer Reported

Curaleaf is described as pursuing a hostile takeover of Aurora Cannabis (NASDAQ:ACB) with an 86% premium that Aurora's board has urged shareholders to reject. A hostile bid bypasses the target's directors and appeals to shareholders directly, usually through a tender or exchange offer. The 86% figure comes from one deals roundup, and neither the per-share price, the form of payment nor the closing deadline was available, so the premium cannot be converted into a dollar value here. Curaleaf has no US exchange listing in the material reviewed, so it carries no tag. The coverage dates the news October 26 to 27, 2026. Because the bid is described as hostile, the first test is how many shareholders tender or vote in favor, which depends on the offer price, the form of payment and the target's own plans.

The Alberta Ruling

A regulator in Alberta dismissed Curaleaf's application to halt Aurora's share program, according to the coverage. In practice Aurora can continue the program while the bid is pending, although the details, such as whether it is a buyback or an issuance, were not given. Companies facing hostile bids often use such tools, along with shareholder rights plans, to raise the price or buy time. Canadian securities regulators review defensive tactics to protect shareholders' ability to decide, which is the usual reason an offeror approaches one first. The decision clarifies who may act next but leaves the bid's merits untouched. If the program was a share issuance, it could dilute the offeror's stake, and if it was a buyback, it could support the price, so the details matter.

Risks and What to Watch

Cannabis takeovers face regulatory hurdles on both sides of the border, since US operators and Canadian licensed producers sit under different rules, and no approval timetable was reported. An 86% premium is large for any takeover, so shareholders will test whether it is a firm intention or an opening position. A contested process can end in a raised offer, a rival bidder or a withdrawal, and each outcome would move the stock sharply. Watch for Aurora's board circular, any change to the offer, further regulator filings and the next quarterly result. Aurora's own financial position, including cash and losses, will shape how shareholders compare the offer with the standalone plan.

Where Things Stand

The answer is that Curaleaf appears to be using a large 86% premium to win shareholder support over the objection of Aurora Cannabis (NASDAQ:ACB)'s board, while the Alberta ruling leaves Aurora's share program in place. The terms, deadline and financing were not captured, so the odds of success cannot be judged. The next catalysts are Aurora's board circular, any raised offer and further regulator filings. The bid is reported and contested, not agreed. This is not investment advice.